BridgeMD
VulVaccin study
EU CTIS ID: 2023-506792-94-00
What this study is testing
To evaluate the efficacy of adjuvant nonavalent HPV vaccination in women who will undergo treatment for (pathology proven) vulvar HSIL in preventing clinical recurrence HSIL up to 24 months.
- Phase III and phase IV (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Women 18 years or older
- Vulvar High-grade Squamous Intraepithelial Lesion (HSIL), histologically proven
- Planned for treatment (surgical, laser or imiquimod) for vulvar High Grade Squamous Intraepithelial Lesion
You likely can't join if
- Prior HPV vaccination
- (Micro-) invasive carcinoma or history of HPV related genital carcinoma (cervix, anal, vulva)
- Pregnancy
- Women allergic to vaccine components
- HIV infection
- Immune compromised patients (currently on immunosuppressive medication)
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.